Allergan Sales, LLC
⚠️ High Risk
FEI: 2011068 • Irvine, CA • UNITED STATES
FEI Number
2011068
Location
Irvine, CA
Country
UNITED STATESAddress
2525 Dupont Dr, , Irvine, CA, United States
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
NO LICENSE
The article is subject to refusal of admission under section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because it appears to be a biological product for which a biologics license is not in effect under the Public Health Service Act, Part F, Subpart 1-Biological Products, Section 351(a), and it is not the subject of an Investigational New Drug application that is in effect. Therefore, it appears to be a new drug under 201(p) of the FD&C Act that it is in violation of section 505(a) of the FD&C Act because it lacks a new drug approval and because it is misbranded under section 502(f)(1)of the FD&C Act because it fails to bear adequate directions for use
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
AGR RX
The article appears to be a prescription drug manufactured in the U.S. and offered for import by other than the manufacturer and reimportation does not appear to have been authorized by the Secretary for use in a medical emergency.
REGISTERED
It appears the device is subject to listing under 510(j) and the initial distributor has not registered as required by 21 CFR 807.20 (a)(5).
DRUG NAME
The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
NO 510(K)
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a post 1976 device for which a Section 510(k)application does not appear to have been determined substantially equivalent or otherwise filed.
DRUG GMPS
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 12/2/2024 | 66VBY99MISCELLANEOUS PATENT MEDICINES, ETC. | Division of Northern Border Imports (DNBI) | |
| 1/16/2024 | 66YDY99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/3/2023 | 66VIY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/13/2023 | 65QAY02BOTOX | 118NOT LISTED | Division of West Coast Imports (DWCI) |
| 12/16/2022 | 65QCK02BOTOX | Division of West Coast Imports (DWCI) | |
| 12/9/2022 | 65QBY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/1/2022 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 10/11/2022 | 65QDY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/27/2022 | 65QCK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/17/2021 | 65QAL02BOTOX | Division of West Coast Imports (DWCI) | |
| 8/27/2021 | 65QDY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/25/2021 | 65QCY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/23/2021 | 65QBY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/10/2021 | 65QDK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/15/2021 | 79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE | Division of Southeast Imports (DSEI) | |
| 11/9/2020 | 79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE | Division of Southeast Imports (DSEI) | |
| 11/26/2019 | 60CDL54BRIMONIDINE TARTRATE (ADRENERGIC) | 27DRUG GMPS | Division of Southeast Imports (DSEI) |
| 7/2/2018 | 65QCK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/6/2018 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 3/6/2018 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 3/6/2018 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 3/6/2018 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 3/5/2018 | 65QCP02BOTOX | Division of Southeast Imports (DSEI) | |
| 2/21/2018 | 65QCK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/20/2017 | 87MOZACID, HYALURONIC, INTRAARTICULAR | Division of Northern Border Imports (DNBI) | |
| 5/27/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 118NOT LISTED | Florida District Office (FLA-DO) |
| 5/27/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 118NOT LISTED | Florida District Office (FLA-DO) |
| 5/27/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 118NOT LISTED | Florida District Office (FLA-DO) |
| 5/27/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 118NOT LISTED | Florida District Office (FLA-DO) |
| 5/27/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 118NOT LISTED | Florida District Office (FLA-DO) |
| 12/1/2014 | 65KCK10BIMATOPROST (PROSTAGLANDIN) | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 9/3/2014 | 65QCY02BOTOX | Cincinnati District Office (CIN-DO) | |
| 10/28/2011 | 64LAK51PREDNISOLONE ACETATE (GLUCOCORTICOID) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 9/7/2011 | 80LDQDEVICE, GENERAL MEDICAL | 118NOT LISTED | New Orleans District Office (NOL-DO) |
| 7/31/2009 | 66VIP99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 7/31/2009 | 55RY68POLYVINYL ALCOHOL (PHARMACEUTIC NECESSITY - VEHICLE) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/4/2006 | 60CIK54BRIMONIDINE TARTRATE (ADRENERGIC) | 179AGR RX | New Orleans District Office (NOL-DO) |
| 3/30/2005 | 62GCY89CYCLOSPORINE (ANTI-INFLAMMATORY) | 179AGR RX | New Orleans District Office (NOL-DO) |
Frequently Asked Questions
What is Allergan Sales, LLC's FDA import refusal history?
Allergan Sales, LLC (FEI: 2011068) has 38 FDA import refusal record(s) in our database, spanning from 3/30/2005 to 12/2/2024.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Allergan Sales, LLC's FEI number is 2011068.
What types of violations has Allergan Sales, LLC received?
Allergan Sales, LLC has been cited for 12 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Allergan Sales, LLC come from?
All FDA import refusal data for Allergan Sales, LLC is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.